NCT04563377

Safety and Immunogenicity of Candidate HIV Vaccines Given Sequentially

A Phase 1/2a Open Label Trial to Assess Safety and Immunogenicity of Candidate T-cell Vaccines ChAdOx1.HTI and MVA.HTI Given Sequentially to Healthy HIV-1/2 Negative Adult Volunteers in Oxford, UK

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: University of Oxford · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary object of the study is to assess the safety profile of candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers. In addition, the study will assess the immune responses generated of the candidate vaccines ChAdOx1.HTI and MVA.HTI administered sequentially in healthy HIV-1/2 negative adult volunteers. 10 healthy, HIV-negative adult volunteers will receive one vaccination of CHAdOx1.HTI followed by a one vaccination of MVA.HTI 8 weeks later.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	ChAdOx1.HTI and MVA.HTI	ChAdOx1. HTI dose 5 x 10\^10 vp MVA.HTI dose 2 x 10\^8 pfu

Timeline

• Start date: 2021-11-01
• Primary completion: 2022-08-16
• Completion: 2022-08-16
• First posted: 2020-09-24
• Last updated: 2022-09-01

Locations

1 site across 1 country: United Kingdom